-
3 weeks ago | 
fapnewstoday.com | Margarida Maia |Ezekiel Lim |Andrea Lobo |Steve Bryson
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to ART001, a gene editing candidate that Accuredit Therapeutics is developing as a one-time treatment for transthyretin (ATTR) amyloidosis, a group of diseases that includes familial amyloid polyneuropathy (FAP).
-
1 month ago | 
fapnewstoday.com | Ezekiel Lim |Marisa Wexler |Lindsey Shapiro
The daily life of a familial amyloid polyneuropathy (FAP) caregiver isn’t always one of set routines. With the nature of the ailment and its painful peripheral neuropathy symptoms, there will be days when new issues arise or symptoms become more severe. Some of these problems may be unforeseen, while others can be prevented with careful attention to diet, activities, and medications. Still, even extreme care and consideration won’t prevent every health concern.
-
2 months ago | 
fapnewstoday.com | Marisa Wexler |Patricia Inacio |Ezekiel Lim |Lindsey Shapiro
Five years of treatment with Onpattro (patisiran) slowed disability progression and maintained quality of life for people with familial amyloid polyneuropathy (FAP) in a long-term clinical trial, a study shows. Although Onpattro can help delay FAP progression, “patients tend not to recover function that is lost before starting treatment,” the researchers wrote.
-
2 months ago | 
fapnewstoday.com | Ezekiel Lim |Andrea Lobo |Steve Bryson
In my last column, I mentioned that my mother-in-law was recently diagnosed with rheumatoid arthritis. She already suffers from the symptoms of familial amyloid polyneuropathy (FAP), including itching and burning sensations in her hands and feet. The pain of her neuropathy symptoms makes it hard for her to walk around, relegating her primarily to a motorized wheelchair. She had suspected for some time that there was something more to her pain, but no one knew what to make of it.
-
Jan 16, 2025 | 
fapnewstoday.com | Ezekiel Lim |Andrea Lobo
For neuropathy patients and caregivers, having a purpose in life may go a long way toward helping us manage peripheral neuropathy. Many familial amyloid polyneuropathy (FAP) patients and caregivers, however, are forced to put a great deal of focus on simply surviving. My mother-in-law has tingling and burning sensations in her hands and lower extremities because of FAP. Her daily routines are therefore difficult at times.
-
Dec 9, 2024 | 
fapnewstoday.com | Katherine Poinsatte |Ezekiel Lim |Andrea Lobo |Marta C. Figueiredo
A single dose of nucresiran, an experimental therapy for familial amyloid polyneuropathy (FAP) and other forms of ATTR amyloidosis, safely resulted in significant and sustained reductions in blood levels of the disease-driving transthyretin (TTR) protein in healthy people. That’s according to interim results from an ongoing, placebo-controlled Phase 1 clinical trial (NCT05661916) presented at the American Heart Association Scientific Sessions 2024, held Nov. 8-10 in Chicago.
-
Nov 18, 2024 | 
fapnewstoday.com | Margarida Maia |Ezekiel Lim |Marisa Wexler |Marta C. Figueiredo
The U.S. Food and Drug Administration (FDA) has given orphan drug designation to AT-02, Attralus’ investigational candidate for the treatment of transthyretin amyloidosis (ATTR), a group of diseases that includes familial amyloid polyneuropathy (FAP).
-
Oct 28, 2024 | 
fapnewstoday.com | Lindsey Shapiro |Ezekiel Lim |Marisa Wexler |Mary Chapman
Adults with familial amyloid polyneuropathy (FAP) living in Canada may soon be able to receive Amvuttra (vutisiran) at little or no cost through public drug plans, the therapy’s developer said. Amvuttra is approved in the country for adult FAP patients with stage 1 or stage 2 polyneuropathy or mild to moderate symptoms of polyneuropathy, or damage to multiple nerves.
-
Oct 17, 2024 | 
fapnewstoday.com | Ezekiel Lim |Margarida Maia |Andrea Lobo
About a month ago, my father-in-law came down with what seemed like a cold. But his condition gradually worsened, which sent him to the hospital. There he was diagnosed with COVID-19. Because he takes on most of the caregiving duties for my mother-in-law, who has familial amyloid polyneuropathy, his recovery put a strain on her and the rest of the family.
-
Oct 16, 2024 | 
fapnewstoday.com | Ezekiel Lim |Margarida Maia |Andrea Lobo |Katherine Poinsatte
My late husband, Aubrey, was diagnosed with hereditary ATTR amyloidosis in 2013 and passed away on May 22, 2022. Those nine years were spent transitioning from having harmony in our marriage to navigating a relationship wrought with challenges. We were encumbered not only by the stress of Aubrey’s failing health, but also by the need to meet each other’s expectations. We were constantly adjusting how we communicated with each other.
